Treatment Study for Children and Adolescents with B-cell Mature Non-Hodgkins Lymphoma Including Burkitt and Primary CNS Lymphomas

What this Trial Is About

Researchers are studying the molecular features and minimal disease detection of B-cell mature Non-Hodgkins Lymphoma B-NHL in children and adolescents. The trial aims to identify very high-risk patients who may need more intensive treatment and those who could avoid aggressive therapy. Another key goal is to evaluate the role of PETCT scans in checking if the lymphoma is fully in remission. The study investigates different risk groups based on disease stage and genetic factors to assess if treatment can be adjusted without lowering survival rates. The trial includes four treatment groups based on disease extent and biology. For patients with very limited disease R1, rituximab is added to possibly allow skipping certain chemotherapy drugs to reduce side effects while maintaining survival. Patients in groups R2 and R3 receive rituximab combined with chemotherapy with dose adjustments to reduce toxicity. The highest risk group R4 receives intensified treatment including rituximab and additional chemotherapy blocks. Rituximab doses are timed before chemotherapy cycles, and treatments are tailored by risk group. Participants will be monitored over several years with assessments including PET-CT scans, laboratory tests for immune recovery, and monitoring of disease markers in bone marrow. Researchers will measure event-free survival at 3 and 7 years, relapse-free survival, response rates after treatment courses, immune system recovery, and vaccination responses. The study also evaluates immune cell populations and infection rates. Safety and treatment effects will be followed closely to understand long-term outcomes in pediatric patients.

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021